"NUMBER NEEDED TO TREAT" ANALYSIS TO ASSESS THE COMPARATIVE OUTCOMES FROM TERIFLUNOMIDE AND DIMETHYL FUMARATE STUDIES IN RELAPSING MULTIPLE SCLEROSIS

被引：0
|
作者：
Leist, T. P. [1 ]
Montalban, X. [2 ]
Miller, A. E. [3 ]
Dive-Pouletty, C. [4 ]
Freedman, M. S. [5 ,6 ]
机构：
[1] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] Genzyme, Chilly Mazarin, France
[5] Univ Ottawa, Ottawa, ON, Canada
[6] Ottawa Hosp Res Inst, Ottawa, ON, Canada
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND13
引用
收藏
页码：A279 / A280
页数：4
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF DIMETHYL-FUMARATE COMPARED TO TERIFLUNOMIDE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS IN ITALY
    Mantovani, L. G.
    Furneri, G.
    Cortesi, P. A.
    Santoni, L.
    Prosperini, L.
    Cardillo, A.
    VALUE IN HEALTH, 2020, 23 : S630 - S630
  • [22] Real world comparison of teriflunomide and dimethyl fumarate in naive relapsing multiple sclerosis patients: Evidence from the Italian MS register
    Zanghi, Aurora
    Avolio, Carlo
    Amato, Maria Pia
    Filippi, Massimo
    Trojano, Maria
    Patti, Francesco
    D' Amico, Emanuele
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 58
  • [23] Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis
    Boz, Cavit
    Terzi, Murat
    Ozer, Bilge
    Turkoglu, Recai
    Karabudak, Rana
    Efendi, Husnu
    Soysal, Aysun
    Sevim, Serhan
    Altintas, Ayse
    Kurne, Asli
    Akcali, Aylin
    Akman, Gulsen
    Yuceyar, Nur
    Balci, Belgin Petek
    Ekmekci, Ozgul
    Karahan, Serap Zengin
    Demirkiran, Meltem
    Altunrende, Burcu
    Turan, Omer Faruk
    GozubatikCelik, Gokcen
    Kale, Nilufer
    Koseoglu, Mesrure
    Ozakbas, Serkan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 36
  • [24] Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis
    Mukhtar, Humza
    Yasmeen, Uzma
    Siddiqa, Sania
    Sarfraz, Zouina
    Sarfraz, Azza
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 65
  • [25] Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis
    Mukhtar, Humza
    Yasmeen, Uzma
    Siddiqa, Sania
    Sarfraz, Zouina
    Sarfraz, Azza
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 65
  • [26] Comparative clinical efficacy of alemtuzumab and ocrelizumab in patients with relapsing-remitting multiple sclerosis: Number needed to treat analyses
    Comi, G.
    Boster, A.
    Alroughani, R.
    Berkovich, R.
    Izquierdo, G.
    Kantor, D.
    Laganke, C.
    Limmroth, V.
    Macdonell, R.
    Moreau, T.
    Sharrack, B.
    Wiendl, H.
    van Wijmeersch, B.
    Margolin, D. H.
    Thangavelu, K.
    Melanson, M.
    Freedman, M. S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 492 - 492
  • [27] Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
    Ozel, Osman
    Vaughn, Caila B.
    Eckert, Svetlana P.
    Jakimovski, Dejan
    Lizarraga, Alexis A.
    Weinstock-Guttman, Bianca
    PATIENT-RELATED OUTCOME MEASURES, 2019, 10 : 373 - 384
  • [28] Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis
    Zhang, Xinke
    Hay, Joel W.
    Niu, Xiaoli
    CNS DRUGS, 2015, 29 (01) : 71 - 81
  • [29] Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis
    Xinke Zhang
    Joel W. Hay
    Xiaoli Niu
    CNS Drugs, 2015, 29 : 71 - 81
  • [30] Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis
    Zagmutt, Francisco J.
    Carroll, Cathryn A.
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2015, 125 (11) : 798 - 807
12345